Evident Vascular, a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by artificial intelligence, today announced the successful closing of its Series B financing with new investors Shangbay Capital and two undisclosed multinational strategics joining founding investor Vensana Capital. The funding will accelerate the development of the Company's advanced IVUS technology designed to enhance vascular imaging and patient outcomes and support 510(k) FDA clearance ahead of U.S. market launch.

Evident Vascular is developing an advanced intravascular ultrasound (IVUS) platform designed to optimize vascular imaging for peripheral and coronary interventions. With the integration of artificial intelligence, the platform enhances image interpretation, streamlines workflows, and drives improved clinical outcomes. Evident Vascular's mission is to empower clinicians with cutting-edge tools that enable precision, efficiency, and superior patient care.